ARCHITECT I2000SR ANALYZER 03M74-97

MAUDE Adverse Event Report

MAUDE data represents reports of adverse events involving medical devices. This maude entry was filed from a foreign,health professional report with the FDA on 2015-12-01 for ARCHITECT I2000SR ANALYZER 03M74-97 manufactured by Abbott Manufacturing Inc.

Event Text Entries

[32451724] Patient identifier did not contain enough spaces for enitre id. The entire id is (b)(6). (b)(4). A followup report will be submitted when the evaluation is complete. Evaluation in process.
Patient Sequence No: 1, Text Type: N, H10


[32451725] The account generated repeatedly reactive architect (b)(6) combo results on a post-mortem sample id (b)(6) (5. 5, 1. 7, 1. 6,1. 6, 1. 7 s/co) that tested nonreactive on another architect analyzer. The sample was also (b)(6) with western blot and rna testing. The post mortem sample was screened for bone transplantation. Bones, tissues and other transplantation materials were lost due to the (b)(6) architect (b)(6) combo results. No specific donor information is known. No impact to recipients was reported.
Patient Sequence No: 1, Text Type: D, B5


[34150973] Upon retrospective review, discovered date of event was inadvertently entered incorrectly on the initial report. This report to update date of event to (b)(5) 2015. An evaluation is in process. A followup report will be submitted when the evaluation is complete.
Patient Sequence No: 1, Text Type: N, H10


[39566291] Additional information was provided during evaluation: reactive architect hiv ag/ab combo results were also obtained on a third architect instrument by using the same reagent lots. This instrument is utilized for clinical studies performed and managed by an abbott clinical studies coordinator. The two post mortem samples were run on this architect instrument for troubleshooting purposes only. No issues were observed with "normal" samples or controls performed on the three architect i2000sr analyzers. An evaluation was performed for both the architect i2000sr analyzer and reagent lots. Architect hiv ag/ab combo evaluation: a review of the product labeling concluded that the issue is sufficiently addressed. The tracking and trending report review determined that there are no related adverse or non-statistical trends for the reagent lots involved in this event and no non-conformances and deviations associated with the affected reagent lots have been identified. A retained reagent kit of lot 54325li00 was tested in a specificity and sensitivity setup. Results of this setup did not implicate that the specificity or sensitivity performance of the lot is negatively impacted. The reagent kit showed normal performance without false reactive results. Additionally, the specificity performance were tested with lot 53118li00 and no (b)(6) were obtained. Based on this data, the performance of the architect hiv ag/ab combo reagent lot 53110li00 and 54325li00 is acceptable. Architect i2000sr evaluation: the field service engineer (fse) proactively cleaned and replaced several parts on the architect i2000sr. No subsequent occurrences of discrepant results were documented after the part replacements and cleaning of the optics. A review of the architect isr05922 service history was performed. No additional contributing factors on or around the date of the event were identified, and no subsequent occurrences of discrepant results were found after the cleaning of the optics and replacement of multiple parts by the fse. The architect system operations manual addresses operational precautions and limitations and addresses probable causes and corrective actions for the troubleshooting of discrepant results. A review of the architect product monitoring review found no similar issues as described in this complaint, and no trend associated with the architect i2000sr erratic result rate was identified. Based on the available information, there is insufficient evidence to reasonably suggest a malfunction of the architect i2000sr. The evaluation did not identify a specific reason, why the customer experienced this problem, but a possible explanation may be that the reactive results were due to sample integrity issues or due to the colour (almost black) of the affected samples. According to the package insert of the assay an important factor to obtain consistency in results is the quality of the sample. Based on this data, it is concluded that the architect hiv ag/ab combo reagent lots, identified in this complaint are performing acceptably, and there is no indication of a deficiency of the architect i2000sr or the various i2000sr parts replaced and/or cleaned.
Patient Sequence No: 1, Text Type: N, H10


MAUDE Entry Details

Report Number1628664-2015-00309
MDR Report Key5258548
Report SourceFOREIGN,HEALTH PROFESSIONAL
Date Received2015-12-01
Date of Report2016-02-24
Date of Event2015-10-19
Date Mfgr Received2016-02-05
Device Manufacturer Date2008-05-13
Date Added to Maude2015-12-01
Event Key0
Report Source CodeManufacturer report
Manufacturer LinkY
Number of Patients in Event0
Adverse Event Flag3
Product Problem Flag0
Reprocessed and Reused Flag3
Health Professional3
Initial Report to FDA3
Report to FDA3
Event Location3
Manufacturer ContactNOEMI ROMERO-KONDOS, RN BSN
Manufacturer Street100 ABBOTT PARK ROAD DEPT. 09B9, LCCP1-3
Manufacturer CityABBOTT PARK IL 600643537
Manufacturer CountryUS
Manufacturer Postal600643537
Manufacturer Phone224667-512
Manufacturer G1ABBOTT MANUFACTURING INC
Manufacturer Street1921 HURD DRIVE
Manufacturer CityIRVING TX 75038
Manufacturer CountryUS
Manufacturer Postal Code75038
Single Use3
Previous Use Code3
Event Type3
Type of Report3

Device Details

Brand NameARCHITECT I2000SR ANALYZER
Generic NameAUTOMATED IMMUNOASSAY ANALYZER
Product CodeNHS
Date Received2015-12-01
Catalog Number03M74-97
OperatorHEALTH PROFESSIONAL
Device AvailabilityY
Device AgeDA
Device Eval'ed by MfgrY
Device Sequence No0
Device Event Key0
ManufacturerABBOTT MANUFACTURING INC
Manufacturer Address1921 HURD DRIVE IRVING TX 75038 US 75038


Patients

Patient NumberTreatmentOutcomeDate
101. Deathisabilit 2015-12-01

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.